The following presentation contains forecasts, future plans, management targets and other forward-looking projections relating to M3, Inc. and/or its group. These statements are drawn from assumptions of future events based on data currently available to us, and there exist possibilities that such assumptions are objectively incorrect and/or may produce differing actual results from those mentioned in the statements.
Furthermore, information and data other than those concerning the Company and its subsidiaries/affiliates are quoted from public information, and the Company has not verified and will not warrant its accuracy or dependency.
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original document
Permalink
Disclaimer
M3 Inc. published this content on 27 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 October 2021 09:57:08 UTC.
M3, Inc. specializes in the provision of online services dedicated to the health field. Net sales (before intra-group eliminations) break down by activity as follows:
- medical marketing support services (40.3%): services enabling doctors and health professionals to search for medical resources, use the latest medical news, exchange opinions, learn about medical products and services and career development, etc. via m3.com., MR-kun, MDLinx and MEDI: GATE;
- support services to medical institutions (16.5%):
- clinical trial related services (10.7%): clinical trial support and clinical trial operations management services;
- human resources services (6.6%);
- other (1.6%): including marketing assistance and surveys of affiliated medical companies via specialized sites.
The balance of sales (24.3%) concerns international activities.
M3, INC. 
